Pacira Pharmaceuticals, Inc.

Pacira Pharmaceuticals (PCRX) is a US-based pharmaceutical company focused on non-opioid, long-acting local anaesthetic products for perioperative pain management. Its flagship offering, EXPAREL, is a long-acting bupivacaine formulation used to control postsurgical pain and reduce opioid use. Investors should note the company is commercially established but relatively small by market-cap (around $989m), which can mean greater sensitivity to quarterly results, product adoption trends, and reimbursement dynamics. Key drivers include wider adoption of non-opioid pain management, potential label or formulation extensions, and any pipeline progress. Offsetting factors include competition from generic or alternative pain therapies, pricing and reimbursement pressures, and clinical or regulatory setbacks. As with any pharmaceutical investment, revenues can be lumpy and the share price volatile. This summary is educational and not personal investment advice; always consider how a stock would fit your risk tolerance and investment horizon.